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Abstract 10 
Antimicrobial resistance is a critical health issue today. Many pathogens have become 
resistant to many or all available antibiotics and limited new antibiotics are in the 
pipeline. Glycopeptides are used as a ‘last resort’ antibiotic treatment for many bacterial 
infections, but worryingly, glycopeptide resistance has spread to very important 
pathogens such as Enterococcus faecium and Staphylococcus aureus. Bacteria confront 15 
multiple stresses in their natural environments, including nutritional starvation and the 
action of cell-wall stressing agents. These stresses impact bacterial susceptibility to 
different antimicrobials. This article aims to review the links between glycopeptide 
resistance and different stresses, especially those related with cell-wall biosynthesis and 
inorganic phosphate metabolism, and to discuss promising alternatives to classical 20 
antibiotics to avoid the problem of antimicrobial resistance. 
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1. Introduction: the problem of antibiotic resistance 
In recent years the world has been facing two important and linked problems: i) the 
emergence and spread of antibiotic resistance in pathogenic bacteria and ii) failure to 
discover new chemotherapeutic agents. Antibiotic resistance in pathogenic bacteria does 35 
not only generate an important economic burden for the healthcare system, but also 
reduces the efficacy of antibiotics and increases mortality. Thus, antibiotic resistance is 
considered a worldwide threat for human health, since once treatable infections may be 
fatal again. There was a time in which clinics were revolutionized by the introduction of 
antibiotics, which enabled the treatment of infections and the performance of invasive 40 
surgeries without fear. Those times have come to an end, and we have already entered 
into what is called the “resistance era” (1). 
The “antibiotic era” started with the discovery of penicillin and sulfonamides in the late 
1920s and 1930s. A “Golden Age” for antibiotic discovery then started, which 
continued until the 1960s. In that period, most of the antibiotic classes used today were 45 
discovered. Penicillin, the first antibiotic of natural origin commercialized, was 
discovered in 1928 by Alexander Fleming (2). After the introduction of penicillin into 
clinics in the 1940s, its extensive use against Streptococcus pneumoniae led to the first 
report on a penicillin-resistant strain in 1967 (3). But the development of resistance had 
been observed before, as Fleming advertised in his Nobel Prize speech in 1945. He had 50 
noted that penicillin resistant microbes were obtained easily in the laboratory, and 
warned that the same thing might occur in the human body. 
Antibiotic resistance is a result of Darwinian selection, and there are no examples of 
antibiotics to which bacteria have not developed resistance within a few years of their 
use; being the emergence of resistance to the last-resort antibiotic, colistin, one of the 55 
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latest examples (4-6). Resistance to antibiotics can be gained by mutations or 
acquisition of antibiotic resistance genes. In the latter, horizontal gene transfer by 
conjugation is considered the most important mechanism, although others processes 
(such as transformation or phage-mediated transduction) might play a larger part than 
previously expected; recently reviewed by von Wintersdorff and co-workers (7). The 60 
spontaneous generation of resistant strains by mutations, even before any exposure to 
the antibiotic, is a phenomenon known since 1955 (8). 
A large number of resistance genes of clinical relevance reportedly have their origin in 
non-pathogenic bacteria (7). In fact, antibiotic resistance genes are as ancient as the 
biosynthetic equivalents, and have been detected in the DNA of 30,000-year-old 65 
permafrost samples, as well as in the microbiome of caves that have been isolated for 
millions of years (9, 10). In spite of being a natural process, the threat of antibiotic 
resistance is increasingly alarming because of the acceleration of its rate of appearance. 
The main factor for this acceleration is the misuse of antibiotics through excessive use 
in human and veterinary clinics, and as growth promoters in farming. This excessive use 70 
has led to an increased transmission of resistance elements that has facilitated the 
selection of resistant bacteria. 
According to the Center for Disease Control and Prevention (CDC), it is estimated that 
more than 2 million people are infected with antibiotic resistant microbes in one year in 
the USA and, of them, more than 23,000 die due to the infection. The prognostics for 75 
the future are also alarming; in 2050, 10 million deaths per year are predicted 
worldwide due to antibiotic resistance (11). Thus, it is clear that the correct use of 
antibiotics is necessary to slow down the rate of the emergence of drug resistance, and 
that a new arsenal of antibiotics is urgently required. However, the introduction of new 
chemotherapeutics into clinical practice has been very slow and only one antibiotic from 80 
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a new family, named teixobactin, has been discovered recently (see below). To overtake 
this problem, several drugs that were discarded in the past are currently gaining 
attention. For example fidaxomycin, originally discovered in the 1970s, was approved 
for use in 2011 by the US Food and Drug Administration (FDA), and has been 
successfully applied to the treatment of Clostridium difficile in recent years (12, 13). 85 
Ancient remedies and natural medicine are also gaining attention for the treatment of 
infections. For example, an “ancientbiotic” from the 10th century has been proven to be 
effective against Staphylococcus aureus (14). Similarly, a natural clay from Canada has 
been shown to act as a potent antibacterial against multi drug-resistant ESKAPE strains, 
an acronym referring to Enterococcus faecium, S. aureus, Klebsiella pneumoniae, 90 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species, which 
are all important pathogens responsible for nosocomial infections around the world (15, 
16). 
2. Cell-wall as an antibiotic target 
The majority of antimicrobials used currently target the bacterial DNA, RNA, protein or 95 
cell-wall biosynthesis. In this section we will focus on drugs acting on the biosynthesis 
of the main component of the cell-wall, peptidoglycan (PG). PG is a polymer composed 
of glycan strands crosslinked by peptides. These glycan strands are formed by 
alternating units of N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid 
(MurNAc). MurNAc is associated with peptides responsible for crosslinking the PG 100 
strands. The crosslink between peptide chains can be direct (in most Gram-negative 
bacteria) or indirect, through an interpeptide bridge (in most Gram-positive bacteria). It 
is important to note that variations in PG composition exist depending on the species, 
for example regarding glycan chain length, the nature of the residues in the peptide stem 
or the length and nature of the residues in the cross-linking bridge (17, 18). In all cases, 105 
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PG confers rigidity to the cell, defining shape and increasing mechanical strength. It 
also serves as a scaffold for other components such as proteins or teichoic acids (17). 
PG biosynthesis involves two different phases: the first takes places in the cytoplasm 
(19) and the second is associated with the cell membrane (20). The first step of PG 
synthesis is the formation of an UDP-N-acetylmuramic acid pentapeptide in the 110 
cytoplasm (see Fig 1). In this phase, MurA and MurB generate UDP-MurNAc from 
phosphoenol pyruvate and UDP-GlcNAc. Subsequently, the ATP-dependent ligases 
MurC, MurD, MurE and MurF link five amino acid residues to form UDP-N-
acetylmuramic acid pentapeptide. MurF then catalyzes the incorporation of the 
dipeptide D-Ala-D-Ala, and also involves the alanine racemase (Alr) and the alanine 115 
ligase (Ddl). The UDP-N-acetylmuramic acid pentapeptide is then anchored to the 
membrane-embedded undecaprenyl phosphate by the action of the phospho-MurNAc-
pentapeptide translocase MraY, generating Lipid I. Addition of GlcNAc to Lipid I by 
the glycosyltransferease MurG yields Lipid II, which is then translocated through the 
membrane to the periplasm. This step requires the activity of proteins named flippases, 120 
which remain unidentified. In fact, controversy exists about which of the potential 
candidates proposed are involved; recently reviewed by Ruiz (21). In the periplasm, 
polymerization and other processing reactions result in the formation of the PG mesh. 
Polymerization of glycan strands and cross-linking between glycan chains takes places 
through transglycosylation and transpeptidation reactions, respectively, which are 125 
catalyzed by penicillin-binding proteins (PBPs). These enzymes receive this acronym 
because they are able to bind penicillin. Please refer to the work by Sauvage and co-
workers (22) for an in-depth review about PBPs structure and role on PG biosynthesis. 
The majority of chemotherapeutic agents used in the clinic inhibit the lipid-linked steps 
of the PG synthetic pathway (see Figure 1), although the cytoplasmic steps are also 130 
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considered good targets for new antibiotics (23). Fosfomycin, useful against both 
Gram-positive and Gram-negative bacteria, is a unique Mur inhibitor currently used in 
the clinic. This compound acts by alkylating a conserved cysteine residue in MurA, 
which results in its irreversible inhibition (24). In addition, several natural products that 
act as MurB or other Mur inhibitors have been discovered; although their specificities in 135 
vivo have not been demonstrated yet (25-27). Most of the known Mur ligase inhibitors 
show little or no antibacterial activity, which might be related with the arrangement of 
the Mur enzymes in multiprotein complexes in vivo (28). D-cycloserine, an analog of 
D-Alanine, targets both Alr and Ddl and is a cornerstone among the second-line 
chemotherapeutic agents in the treatment of multi drug-resistant Mycobacterium 140 
tuberculosis infections (29). The limited use of D-cycloserine is due to the prevalence 
of neurological side effects associated with its application (30, 31). Although MraY is 
an essential enzyme and is the target of several antibiotics (tunicamycin, mureidomycin, 
liposidomycin, capuramycin and michellamine B), no chemotherapeutic drugs directed 
against this enzyme are currently in clinical use (32-36). No specific ligands have been 145 
developed to target proteins involved in flipping Lipid II across the membrane. 
Regarding the membrane-linked steps of PG biosynthesis, the complex moenomycin 
(also known as flavomycin) and the antibiotic ramoplanin inhibit the 
transglycosylation steps (37, 38).  Moenomycin is used for animal feeding and has been 
reported to be effective against Helicobacter pylori (39). Ramoplanin shows potent 150 
activity against C. difficile and is being developed as an alternative treatment for this 
disease (40, 41). The main group of antibiotics that act during the membrane phase of 
PG biosynthesis is the β-lactams, which share a common core (the β-lactam ring) and 
display a broad spectrum of antibacterial activity. β-lactams are analogs of the D-Ala-D-
Ala dipeptides and thus are recognized by transpeptidases, resulting in the irreversible 155 
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inhibition of these enzymes (42-44). Glycopetide antibiotics, which will be further 
described in the next section, target the D-Ala-D-Ala termini on PG peptides and its 
precursor Lipid II. Whilst β-lactams can be used against Gram-positive and Gram-
negative bacteria, glycopeptides are only effective against Gram-positive bacteria; 
mainly due to the low permeability of the outer membrane in Gram-negatives 160 
(hampering the diffusion of the glycopeptide molecule). Other antibiotics used in the 
clinic that target PG biosynthesis are: bacitracin, which inhibits the recycling of 
undecaprenyl phosphate (45) and lipopeptides, such as daptomycin, which induces 
depolarization of the cell membrane (46). The targets of all the antibiotics mentioned 
above are depicted in Figure 1. 165 
Recently, an 11-aminoacid peptide (named teixobactin) from a new genus related to 
Aquabacteria (provisionally named Eleftheria terrae) has been found to inhibit cell-
wall biosynthesis by binding to Lipid II and Lipid III, which are precursors of teichoic 
acids (47). This compound is effective against methicillin-resistant S. aureus (MRSA) 
in mice and other Gram-positive bacteria in cell culture. Nevertheless, researchers 170 
should be cautious since it is still in early-stage development (48, 49). 
3. Glycopeptides: a very important class of antibiotics  
Glycopeptide antibiotics are highly important for the treatment of infections caused by 
Gram-positive bacteria, and usually represent the only treatment for infections caused 
by multi drug-resistant strains of enterococci, streptococci and staphylococci. In fact, 175 
the two main glycopeptides, vancomycin and teicoplanin, are widely used in the 
treatment of MRSA and penicillin-resistant S. pneumoniae. 
Antibiotics from this family share a common heptapeptide structure and are synthetised 
by non-ribosomal peptide synthetases (NRPS). They are divided into five structural 
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subclasses according to the residues at positions 1 and 3 of the heptapeptide (50). These 180 
groups include not only the natural products vancomycin (Type I) and teicoplanin (Type 
IV), but also the semisynthetic glycopeptides, such as telavancin, oritavancin and 
dalbavancin. Please refer to the work by Nicolau and co-workers (50) for an extensive 
review on natural glycopeptides and semisynthetic derivatives. Ristocetin is a naturally 
occurring glycopeptide that is not used as an antibiotic treatment but it has a clinical 185 
application. This compound is used in the detection of the platelet type-von Willebrand 
disease, since it triggers platelet aggregation in patients who lack the platelet factor 
receptor (51). 
In Gram-positive bacteria, glycopeptides can diffuse though the cell-wall to reach the 
particular target(s). As mentioned in the previous section, this family of drugs acts by 190 
binding to the D-Ala-D-Ala dipeptide termini of PG and its precursor Lipid II. As a 
result of this binding, there is reduced activity of transglycosylases and transpeptidases 
that catalyze the incorporation of new units into the nascent PG chains and the cross-
linking events, respectively (52), leading to the eventual weakening of the cell-wall and 
a blockage in cell division, resulting in cell death. 195 
Some glycopeptides, such as vancomycin, are able to dimerize in solution, which 
enhances their antibacterial activity (53-55). On the other hand, teicoplanin increases its 
antibiotic activity with a long hydrocarbon chain in its structure that allows drug 
anchoring to the cell membrane. This enhances the concentration of antibiotic on the 
membrane surface and the interaction with Lipid II. In addition, this lipophilic group 200 
can affect the membrane potential leading to its disruption (55-57). 
4. Main glycopeptide antibiotics 
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Vancomycin was discovered in 1955 at Eli Lilly (Indianapolis, USA), constituting the 
first member of the glycopeptides family (58). It was approved for the use of penicillin-
resistant staphylococcal infections by the FDA in 1958. The use of vancomycin started 205 
to increase in the early 1980s, rising rapidly during the 1980s and early 1990s (59). The 
first attempts to reduce its use in response to the spread of vancomycin-resistant bacteria 
resulted in a slight decline in use after 1994. Currently, vancomycin is used to treat 
complicated infections with MRSA (60) and C. difficile (61). 
Teicoplanin is a lipoglycopeptide complex composed of 6 closely related compounds 210 
(62, 63). The ratio of each component in the mixture varies depending on fermentation 
conditions and this also affects its protein binding characteristics. Thus, the therapeutic 
implications for critical patients require a stronger standardization of the final product 
(64-66). Although teicoplanin was approved in Europe in 1988 and is also available in 
other countries, this antibiotic is not used in the USA. 215 
Oritavancin is a derivative of the Type I glycopeptide chloroemomycin approved by 
the FDA in 2014. It shows a unique mechanism of action as it maintains the binding 
affinity for the modified peptide termini of vancomycin-resistant bacteria (see below). 
Moreover, it inhibits transpeptidation by steric hindrance of the transpeptidases, 
reducing cell-wall integrity (67). In addition, oritavancin generates depolarization and 220 
permeabilization of the membrane leading to cell death (68). 
Telavancin was approved by the FDA in 2009. Derived from vancomycin, telavancin 
adds an additional property with respect to vancomycin: in being able to disrupt the 
cell-membrane potential of Gram-positive bacteria. It is more potent than vancomycin 
against a number of Gram-positive bacteria. In addition, it shows stronger binding to D-225 
Ala-D-Ala termini and cell membranes, increasing its effectiveness against MRSA and 
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VanB vancomycin-resistant enterococci strains (see below). It is like oritavancin, in that 
it disrupts membrane potential and permeabilizes the membrane (69, 70). 
Dalbavancin is a derivative of a teicoplanin-like glycopeptide that was developed in the 
1990s but not approved by the FDA until 2014. Like teicoplanin, this antibiotic is a 230 
mixture of 5 related compounds. It also shows improved D-Ala-D-Ala binding 
properties, although it does not appear to destabilize cell membranes (71). 
The structures of the main compounds cited in this work are depicted in Figure 2. 
5. Mechanisms of glycopeptide resistance and transcriptional regulation 
The unique mode of action of glycopeptide antibiotics was promising and therefore a 235 
slow development of resistances in pathogenic bacteria was expected. In fact, it took 
over 30 years after the introduction into the clinic to find the first vancomycin-resistant 
enterococci (VRE) strains (72, 73). This is a very long period in comparison to the 
emergence of other cases of antibiotic resistance. Nowadays, VRE have become 
significant nosocomial pathogens worldwide, mainly due to their adaptability in hospital 240 
environments and the limited treatment options. 
The main mechanism of glycopeptide resistance relies on two main factors: i) the 
substitution of the target D-Ala-D-Ala by other low affinity termini (D-Ala-D-Lac or D-
Ala-D-Ser) and ii) the removal of D-Ala-D-Ala precursors. The second factor is 
especially important since the production of both high and low affinity precursors does 245 
not confer resistance (74, 75). Substitution of D-Ala-D-Ala by D-Ala-D-Lac decreases 
binding affinity 1000-fold (76, 77) whilst substitution with D-Ala-D-Ser reduces 
binding affinity to a lower extent (78). Ten types of glycopeptide resistance 
determinants (VanA, VanB, VanC, VanD, VanE, VanF, VanG, VanL, VanM, and 
VanN) have been reported and well characterized on the basis of phenotypic and 250 
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genotypic criteria (79, 80). VanA, VanB, VanD, VanF and VanM types are 
characterized by the formation of D-Ala-D-Lac whilst VanC, VanE, VanG, VanL and 
VanN types rely on the formation of D-Ala-D-Ser. Among all of the known types, 
VanA and VanB genotypes predominate worldwide (80). 
Other mechanisms contributing to vancomycin resistance are found in the so-called 255 
vancomycin-intermediate S. aureus (VISA). These strains normally have thicker cell-
walls and an increased number of free D-Ala-D-Ala groups which act as false targets for 
vancomycin binding. Consequently, the amount of antibiotic available to reach the cell-
wall synthesis machinery is significantly reduced (81). A higher risk is the vancomycin 
resistant S. aureus (VSRA) strains. The transfer of vancomycin resistance genes (van) 260 
from VRE to S. aureus has been demonstrated in vitro and in animal models (82). The 
first described case of a fully vancomycin-resistant MRSA strain in humans was 
reported in 2002 and, worryingly, there have been an increasing number of cases in the 
subsequent years (83, 84). Several national healthcare systems recommend that 
glycopeptide treatments should be limited to those patients with known MRSA 265 
infections in order to limit appearance of new glycopeptide-resistant strains (85). 
Teicoplanin, telavancin and dalbavancin are effective against VanB strains, but not 
against VanA strains, since these three glycopeptides induce expression of the vanA 
operon but not that of vanB operon (79, 86). On the other hand, oritavancin is effective 
against both VanB and VanA strains (87). Oritavancin interacts with both Lipid II and 270 
the pentaglycine bridge segment of the nascent PG (67, 88). Despite being approved 
recently as a promising alternative to older counterparts, resistance to oritavancin is 
likely to emerge in the future since it has already been observed in vitro (89). To extend 
the lifetime of glycopeptides, a similar approach to that used for β-lactam antibiotics by 
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using β-lactamase inhibitors, is being developed. Inhibitors of the VanX dipeptidase, 275 
involved in hydrolyzing D-Ala-D-Ala, have been designed against VRE (90). 
The vanX gene forms part of the core of the main van clusters, which are normally 
composed of five genes (vanSRHAX). Depending on the van cluster there are different 
accessory genes, such as vanY and vanZ in VanA types or vanY and vanW in VanB 
types. The vanSR genes encode a two-component system that regulates the 280 
transcriptional activation of all the van genes of the cluster (91). vanHAX encodes the 
enzymes that collectively reconstruct the bacterial peptidoglycan to terminate in D-Ala-
D-Lac, in place of the canonical D-Ala-D-Ala, which is required for vancomycin 
binding and subsequent antibiotic action. vanH encodes a dehydrogenase that converts 
pyruvate to D-Lac (92), vanA codes for a D-Ala-D-Lac ligase (93), and vanX encodes a 285 
D,D-dipeptidase that cleaves D-Ala-D-Ala dipeptides to ensure that only altered 
peptidoglycan precursors terminated in D-Ala-D-Lac are accumulated (94). 
In VanA and VanB types, exposure of cells to vancomycin triggers autophosphorylation 
of VanS on a histidine residue (VanS-P). Phosphorylation of VanS results in the switch 
from phosphatase to kinase activity. VanS-P phosphorylates VanR, resulting in the 290 
accumulation of VanR-P, which, in turn activates transcription from van promoters. In 
the absence of vancomycin, the constitutive phosphorylation of the response regulator 
VanR is suppressed by the phosphatase activity of VanS (see Figure 3). Although the 
sensor kinase is presumed to detect the signal, a direct interaction between vancomycin 
and VanS has only been demonstrated in a few bacteria, with Steptomyces coelicolor 295 
being one of the first reported (95). VanS is not essential for the full activation of the 
van promoters, since VanR can be phosphorylated independently by acetylphosphate or 
other kinases encoded by the host chromosome (89). To date, VanR is the only 
transcriptional activator that has been shown to activate the transcription of the 
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vancomycin-resistance genes. However, in light of recent studies, it has been noted that 300 
transcriptional regulation of vancomycin regulation is not as simple as several van 
promoters regulated by a single transcriptional regulator. For instance, induction of 
vancomycin resistance is highly influenced by the inorganic phosphate concentration of 
the culture media in some actinomycetes such as S. coelicolor and Streptomyces 
lividans (see below). 305 
6. Pho regulon: a phosphate dependent global response 
Inorganic phosphate (Pi) is an essential nutrient that forms part of many of the key 
components within the cell, such as nucleic acids or phospholipids. Pi is involved in 
many important cellular processes, including energy metabolism and intracellular 
signalling. Despite the essentiality of Pi for life, this nutrient is normally found at very 310 
low concentrations in its free form in the environment, especially in soils. To adapt and 
survive in Pi scarcity, bacteria have evolved an array of biochemical and physiological 
responses aimed to secure this nutrient. To date, the main known mechanism 
responding to Pi starvation is the Pho regulon, which constitutes a very efficient and 
sensible regulatory mechanism in bacteria. 315 
The Pho regulon was first characterised in E. coli, and later in many other bacterial 
species (96). It is controlled by a two-component regulatory system comprising an 
inner-membrane histidine kinase sensor protein (PhoR) and a cytoplasmic 
transcriptional response regulator, named PhoB in E. coli and PhoP in Bacillus subtilis 
(97, 98). In E. coli, under Pi limitation, PhoB is activated by PhoR acting as a kinase, 320 
but under Pi-replete conditions, PhoB activation is interrupted by PhoR acting as a 
phosphatase (99). Another protein, PhoU, is required for PhoB dephosphorylation under 
Pi-rich conditions in an unknown manner. In E. faecium, PhoB can be phosphorylated 
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by the sensor kinase VanS, suggesting cross-talk between the response to Pi starvation 
and vancomycin resistance in this bacterium (100). The Pi signalling pathway in B. 325 
subtilis includes a positive feedback loop between the PhoP-PhoR and ResD-ResE two-
component systems (101). Alternative players are also involved in this network, such 
as: i) the Spo0B-Spo0A two-component system (102), ii) the AbrB and ScoC transition 
state regulators (103, 104) and iii) an intermediate of the teichoic acid synthesis 
pathway (105).  330 
In all cases, upon Pi scarcity the response regulator is phosphorylated on an aspartic 
acid residue by the sensor kinase. The phosphorylated response regulator is able to bind 
to specific sequences on the DNA and activate or repress the transcription of the target 
genes. These specific sequences, known as PHO boxes, were first characterized in E. 
coli (106). In most bacteria the PHO boxes are defined as 11-nucleotide sequences 335 
composed of seven well conserved and four less conserved nucleotides (107). The PHO 
boxes are normally found in genes encoding extracellular enzymes capable of obtaining 
Pi from organic phosphates, Pi-specific transporters and enzymes involved in storage 
and saving of the nutrient. However, these sequences have also been found in a wide 
range of other genes that are not directly related to Pi metabolism, revealing a 340 
surprisingly diverse role for the Pho regulon, not only as a regulator of Pi assimilation, 
but also as a master regulator of the cell (108). Indeed, the Pho regulon is involved in 
regulation of nutritional cross-talk, secondary metabolite production and pathogenesis, 
among other important cell processes (109). 
7. Links between the Pho regulon and pathogenesis 345 
Bacterial pathogens of humans, animals and plants normally have to adapt to Pi-limiting 
and/or Pi-rich environments in the host depending on the site of infection. There are 
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numerous studies that report links between Pi regulation and pathogenesis; see the 
following references (110-112) for details. 
The Pho regulon can influence virulence by increasing toxin production, biofilm 350 
formation, acid tolerance and resistance to antimicrobial compounds, among other 
processes. In some bacteria, the Pho system is able to respond to external acidity by 
controlling the transcription of genes involved in the protection against the low pH 
environments of the stomach or the gut (113). In Vibrio cholera, the regulatory cascade 
leading to toxin production is repressed by PhoB under Pi-limiting conditions, while 355 
under the normally high Pi conditions of the intestine, the regulatory cascade is active, 
leading to the production of toxins (114). A link between Pi regulation and biofilm 
formation has been reported in many different bacteria, including Agrobacterium 
tumefaciens, Proteus mirabilis, P. aeruginosa, E. coli and V. cholerae (115-118). 
Biofilms are formed by a matrix of extracellular polymers in which a number of mixed 360 
microbial populations are embedded. The advantages of these communities for the 
bacteria are numerous, and include: tolerance to environmental stresses, resistance to 
antimicrobial agents, accumulation of virulence factors, nutrition, adhesion, etc (119, 
120). However, involvement of Pi regulation in antibiotic resistance by distinct 
mechanisms to those depending on the protection of biofilms has also been reported 365 
(see next section). 
    8. Glycopeptide resistance is highly influenced by Pi. 
A considerable number of studies have reported that the biosynthesis of most antibiotics 
is regulated by Pi; reviewed by Martín (121). There are also studies that establish links 
between Pi regulation and antibiotic resistance. For instance, oxytetracycline production 370 
in Streptomyces rimosus and its corresponding resistance events seem to have a simple 
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mechanism of Pi regulation, which ensures that resistance to the produced antibiotic 
increases in proportion to its biosynthesis (122). In addition, inactivation of the high-
affinity Pi transporter gene (pstS) led to increased penicillin susceptibility in 12 
independent clinical isolates of S. pneumoniae (123), as well as in several pathogenic E. 375 
coli strains (110). Similarly, a point mutation of another Pi transporter (pitA) in S. 
aureus caused enhanced tolerance towards daptomycin and various combinations of 
other drugs. This increased tolerance was accompanied by elevated intracellular 
concentrations of Pi and polyphosphate, pointing to a correlation between intracellular 
Pi and drug tolerance (124). Furthermore, increased sensitivity to vancomycin and 380 
different cationic antimicrobial peptides has been described in M. tuberculosis upon 
inactivation of the phoU homolog gene (phoY2), which is involved in the activation of 
the Pho regulon (125). In E. coli, it has been shown that accumulation of phosphatidic 
acid (an intermediate of phospholipid biosynthesis) increases resistance to vancomycin 
(126). Changes in phospholipid composition had previously been shown to increase 385 
resistance to moenomycin and vancomycin in S. aureus (127). In addition, inactivation 
of the stringent response in P. aeruginosa and E. coli enhances their susceptibility to 
several antimicrobials in antibiotic-treated animals (128). Although the stringent 
response is normally activated by amino acid deprivation, a variety of other nutritional 
stresses, such as Pi depletion, can also activate it (129). This culminates in an increased 390 
production of the alarmone guanosine 5'-(tri)diphosphate 3'-diphosphate [(p)ppGpp], 
growth arrest and the expression of resistance genes. The synthesis of ppGpp has been 
linked to vancomycin resistance in E. faecalis since mutants that were unable to 
synthesize ppGpp showed an increased susceptibility to vancomycin (130). 
Recently, the complexities of vancomycin resistance regulation in Streptomyces have 395 
been reviewed (131). S. coelicolor and S. lividans display a very strong Pi regulation of 
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vancomycin resistance. In these bacteria, vancomycin resistance is almost blocked with 
Pi concentrations above 0.25%, suggesting a key role of this nutrient in the repression 
of vancomycin resistance (132). S. coelicolor and S. lividans do not produce 
glycopeptide antibiotics but they have a VanB-type cluster, which confers inducible 400 
resistance to vancomycin, but not to teicoplanin (133). The Pi regulation of vancomycin 
resistance is not PhoP-dependent since similar minimum inhibitory concentrations were 
obtained in S. coelicolor parental and ΔphoP mutant strains under distinct Pi 
concentrations (132). This Pi regulation was not observed in the vancomycin-producer 
Amycolatopsis orientalis strain (132). Santos-Beneit and co-workers (134) were able to 405 
generate a S. coelicolor mutant strain (SCO2594::Tn5062) that lacked the Pi control 
over vancomycin resistance. The function of the SCO2594 gene product is unknown but 
appeared to be related with cell-wall metabolism since the mutant displayed cell-wall 
synthesis defects. Furthermore, the mutant also showed an increased transcription of 
genes putatively involved in teichoic acid synthesis and export as well as of regulators 410 
associated with the response to cell-wall-perturbing stresses. The role of SCO2594 in 
cell-wall metabolism and its downstream consequences on vancomycin resistance has 
not been yet elucidated, but there is a clear connection between this protein, Pi 
regulation, cell-wall metabolism and vancomycin resistance. Interestingly, the 
SCO2594::Tn5062 mutant (in the presence of vancomycin) not only up-regulates 415 
transcription of the van genes, but also that of three putative small non-coding RNAs 
(sRNAs) within the van cluster; one of them being located in the promoter region of the 
vanRS regulatory genes (134). sRNAs have been postulated to play crucial roles in the 
control of gene expression in response to environmental changes, stress, and in 
virulence (135, 136). The role of these sRNAs on vancomycin resistance control is 420 
currently under investigation.  
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9. D-alanylation of cell-wall components and Pi control: teichoic acids. 
The peptidoglycan layers protect Gram-positive bacteria from osmotic lysis and 
constitute a barrier against toxic compounds (137). As described before, peptidoglycan 
also functions as a scaffold for the attachment of proteins, capsular polysaccharides and 425 
wall teichoic acids (WTAs). In order to save Pi, some bacteria are able to replace the Pi-
rich WTAs with Pi-free teichuronic acids. This process is regulated by PhoP, which in 
B. subtilis initiates teichuronic acid synthesis under Pi starvation through activation of 
the tuaA-H operon and reduces WTAs synthesis through repression of tagAB (138). It 
has been demonstrated that the Pi-dependent PhoR-PhoP activation signal may emanate 430 
from WTA metabolism in B. subtilis (105). Consequently, the PhoR kinase domain 
appears to monitor the cellular level of a WTA synthetic intermediate through an 
interaction with the protein. This intermediate could inhibit PhoR autokinase activity 
during growth under Pi-replete conditions and, consequently, the Pho response. 
Changes in the structure and metabolism of WTAs have been noted to influence 435 
vancomycin resistance, cell-wall turnover and autolysis in different bacteria. In 
addition, some biochemical modifications of these compounds, such as D-alanylation, 
also impact antibiotic resistance in bacteria. D-alanylation of cell-wall components 
(such as WTAs and lipoteichoic acids) results in a net positive charge on the cell-wall, 
which is crucial for many functions of Gram-positive bacteria (139). As mentioned 440 
before, one important effect of this biochemical modification is its influence on the 
resistance to antimicrobial peptides and antibiotics. For example, D-alanylation of cell-
wall components is somehow involved in the resistance of Clostridium butyricum to 
some cationic antimicrobial peptides and lysozyme (140). Similarly, it has been shown 
that the D-alanylation of WTAs reduces vancomycin binding to the cell-wall in S. 445 
aureus (141). In this bacterium, as well as in S. pneumoniae, loss of one or more WTAs 
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genes resulted in not only a reduced cell-wall Pi content or aberrant cell morphology but 
also in an increased susceptibility of the cells to several antibiotics (142-145). 
Therefore, WTAs constitute very important compounds in Gram-positive bacteria as: i) 
structural components of the cell-wall, ii) inducers of essential nutritional starvation 450 
responses (such as the Pho response), and iii) protective agents against cell-wall 
damaging compounds.  
    10. Links between glycopeptide resistance and: a) cell envelope stress, b) 
autolytic activity, c) antibiotic synthesis 
a) Cell envelope stress 455 
As described before, resistance to vancomycin can be acquired by several different 
mechanisms. The most common involves conversion of cell-wall precursors ending in 
D-Ala-D-Ala to D-Ala-D-Lac or D-Ala-D-Ser (146). Another mechanism by which 
resistance can be acquired is through mutation of sigma factors and endogenous two-
component signal transduction systems that control normal cell-wall metabolism (such 460 
as WalRK), or the cellular response to cell-wall damage, like VraRS and GraRS (147-
150). For an in-depth review of the link between stress and antimicrobial resistance 
refer to Poole (151). 
VraSR is a cell envelope stress responsive two-component system that is induced by 
cell-wall-active antibiotics (including glycopeptides). Inactivation of this system 465 
increases β-lactam, bacitracin, fosfomycin and glycopeptide (vancomycin and 
teicoplanin) susceptibility in MRSA strains (152). Mutations in vraRS leading to up-
regulation of the VraSR-dependent cell-wall stress stimulon are also commonly 
observed in VISA strains (153). The VraSR homologues in B. subtilis and 
Streptococcus mutans (LiaRS and LiaFRS, respectively) are also induced by cell-wall-470 
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active antibiotics and their inactivation also generate susceptible phenotypes to these 
agents (154, 155). 
GraRS is another cell envelope stress responsive two-component system in S. aureus, 
which has been linked to vancomycin resistance (156, 157). Overexpression of graRS is 
reported in clinical VISA strains and, conversely, graRS knockout mutants show 475 
increasing susceptibility to vancomycin (156, 158). Although it is not yet completely 
known, glycopeptide resistance supported by GraRS appears to arise from an increased 
net positive surface charge as a consequence of the induction of genes associated with 
D-alanylation of WTAs (among other GraRS-dependent cell-wall modifications). This 
positive net charge would reduce the binding capabilities of cationic agents such as 480 
vancomycin (158). Nevertheless, in most cases, the stress induced effectors that 
promote resistance and/or recruit resistance determinants are yet unknown.  
Links between cell envelope stress and glycopeptide resistance have also been described 
in different species of actinobacteria such as in Corynebacterium, Mycobacterium and 
Streptomyces. In M. tuberculosis, the SigE protein has been shown to be involved in the 485 
protection from cell envelope stress and to confer basal levels of resistance to 
vancomycin. sigE was induced by subinhibitory concentrations of vancomycin in this 
bacterium (159). The authors showed that a M. tuberculosis sigE mutant was more 
sensitive to vancomycin when compared to the wild-type parental strain. In 
Corynebacterium glutamicum, deletion of sigE increased cellular sensitivity to 490 
magnesium deficiency, lysozyme, SDS, EDTA, heat and antibiotics, including nalidixic 
acid, penicillin and vancomycin (160). In S. coelicolor, cell-wall hydrolytic enzymes 
and cell-wall acting antibiotics (such as penicillins and glycopeptides) also induce the 
sigE signal transduction system (161). In a similar manner to M. tuberculosis and C. 
glutamicum, vancomycin resistance is significantly decreased in a S. coelicolor sigE 495 
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null mutant, pointing to a conserved high influence of this sigma factor in glycopeptide 
resistance (162). 
Other cell envelope stress responsive proteins that might be implicated in vancomycin 
resistance are SigW (a sigma factor that responds to a variety of cell envelope stresses), 
SigB (a sigma factor involved in general stress response) and WhiB (a transcriptional 500 
regulator involved in diverse aspects of the biology of actinomycetes, including 
pathogenesis, antibiotic resistance and the control of development). SigW has been 
linked to fosfomycin, vancomycin and ampicillin resistance in B. subtilis, with sigW 
deletion mutants showing increased susceptibility to these agents (148). Disruption of 
sigB highly increased vancomycin susceptibility in S. coelicolor (162) and S. aureus 505 
(163). Finally, whiB was one of the genes more transcriptionally induced by 
vancomycin (apart from the van genes) in a highly vancomycin-resistant S. coelicolor 
mutant (134). Although WhiB has not been described as a specific cell envelope stress 
regulator in Streptomyces (164), it appears to be linked to cell-wall stress in other 
species. For example, WhiB homologs in Corynebacterium diphtheriae and M. 510 
tuberculosis have been implicated in key stages of pathogenesis, protection to cell-wall 
damaging agents and antibiotic resistance (165, 166). A summary of the link between 
stress response regulators and glycopeptide resistance is shown in table 1. 
b) Autolytic activity 
The complexities of the regulation of autolytic activity versus glycopeptide resistance 515 
are manifested by many examples in the scientific literature. For example, it has been 
noted that the autolytic activity of some glycopeptide-intermediate S. aureus strains 
(GISA) is reduced compared to that of the glycopeptide-susceptible strains (167). In this 
sense, vancomycin-dependent inhibition of cell-wall turnover and autolysis was 
23 
 
described in a highly vancomycin-resistant S. aureus mutant, resulting in the 520 
accumulation of cell-wall material and the inhibition of daughter cell separation (168). 
Vancomycin was also described to block the in vitro hydrolysis of cell-walls by 
autolytic enzyme extracts and some lytic enzymes such as lysostaphin and mutanolysin. 
Furthermore, it has been reported that decreased autolytic activity is involved in the 
reduced tolerance of a series of GISA isolates to vancomycin (169). All together, these 525 
findings indicate an important interconnection between glycopeptide resistance and cell-
wall lytic activity. 
c) Antibiotic synthesis 
Glycopeptide antibiotics also affect other important cellular processes, such as antibiotic 
synthesis. This is not unexpected since antimicrobials themselves are growth-inhibiting 530 
stressing agents that normally elicit protective responses in bacteria, including (as 
previously mentioned) stress-dependent recruitment of resistance determinants and (as 
shown in this section) eventual activation of antibiotic biosynthesis. Using 
transcriptomic analyses in S. coelicolor, Hesketh and co-workers (162) observed the 
upregulation of genes involved in the biosynthesis of the antibiotics actinorhodin (Act), 535 
undecylprodigiosin (Red) and the calcium-dependent antibiotic (CDA) 30 min after the 
exposure of the cells to vancomycin. In another study, Santos-Beneit and co-workers 
(134) also reported a large induction of Act and Red synthesis in response to 
vancomycin, as well as a significant increase in the antibiotic production yields in a 
highly vancomycin-resistant mutant strain (see Figure 4). 540 
11. Future perspectives 
The phenomenon of antimicrobial resistance is a critical health issue today as the World 
Health Organization currently recognizes. Indeed, most bacteria have developed some 
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level of resistance to antibiotics. Worse still is the fact that many clinically important 
pathogens have developed resistance to many, or even all, available antibiotics. The 545 
problem of antimicrobial resistance is further complicated by the continued, decades 
long, lack of significant numbers of novel antimicrobials in drug development pipelines 
or clinical practice, making the development of alternative strategies to prevent 
pathogenesis even more crucial. One possibility is the screening of novel antimicrobial 
compounds generated by either chemical synthesis or natural production. Another 550 
outlook is the development of new derivatives of the most important antibiotics used in 
clinics, such as glycopeptides. For example, distinct glycopeptide derivatives with 
increased antibiotic properties have been reported (170-172). 
Alternatively, the very strong Pi regulation of vancomycin resistance reported in S. 
coelicolor and the transcriptional induction of putative sRNAs within its van cluster 555 
constitutes an unprecedented phenomenon of interconnection between antibiotic 
resistance, nutritional stress and sRNA regulation. Characterization of new players 
(including sRNAs) involved in antibiotic resistance could contribute to the elucidation 
of new mechanisms of antibiotic action and to the designing of novel antibiotics and/or 
antimicrobial strategies, such as “antisense RNA therapy” (173-175). Since antibiotic 560 
discovery is economically challenging for pharmaceutical companies (due to the 
development of resistance, among other obstacles), blocking and/or reducing the 
problems of antimicrobial resistance will depend on developing new effective strategies. 
 
  565 
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Legend to the Figures 
Figure 1: Scheme showing the targets of the most important cell-wall acting 
antibiotics. 
Figure 2: Structure of the main compounds cited in this review. 
Figure 3: A model for the function of the vancomycin resistance VanSR two-570 
component signal transduction system in VanA and VanB-type strains. In the 
absence of antibiotic, VanS acts as a phosphatase to suppress the levels of VanR∼P. In 
the presence of antibiotic, VanS switches the phosphatase activity into a kinase activity, 
leading to the accumulation of VanR∼P (the activated form of VanR) and to the 
activation of the van genes. Activation of the van genes is responsible for the 575 
substitution of the normal cell-wall precursors ending in D-Ala-D-Ala to D-Ala-D-Lac 
which reduces vancomycin binding affinity ∼ 1000-fold. 
Figure 4: Vancomycin disc diffusion assay of S. coelicolor SCO2594::Tn5062. For 
the assay, using MMCGT+P medium (134), Streptomyces spores were homogenized 
into 5 mL of warm medium (containing 7 gr L
-1
 of agar) and poured as a thin layer over 580 
a solid layer (20 mL) of medium containing 14 gr L
-1
 of agar. After solidification of the 
added layer, a commercial vancomycin disc (containing 30 μg of the antibiotic) was 
placed on the plate. The result was evaluated after 3 days of incubation at 30 °C. Note 
the Red induction (i.e. undecylprodigiosin production) of the embedded bacteria around 
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